Brepocitinib taken by mouth for adults with skin sarcoidosis
Tests brepocitinib taken by mouth in adults with cutaneous sarcoidosis.
Key facts
- Who runs it
- Priovant Therapeutics, Inc.
- Where
- Coventry, London, and Manchester, United KingdomSee the 3 sitesAlso in 8 other countries, 54 sites
- Trial code
- Registry title
- A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 168 people, planned
- Started
- 9 Apr 2025
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oral Brepocitinib
- Oral Placebo
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sarcoidosis of the skin (cutaneous sarcoidosis). It tests brepocitinib pills against a placebo (dummy pill).
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Cutaneous sarcoidosis confirmed by a skin sample (biopsy) with typical findings. A CSAMI activity score of ≥ 10 is needed.
Main reasons for not taking part
- Past cancer, except basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the uterine cervix fully removed, with no return for ≥ 1 year
- High risk of blood clots or heart and blood vessel disease
- High risk of shingles (herpes zoster)
- Active or recent infection
- Weight not between 40 kg (88 lb) and 130 kg (287 lb), or body mass index (BMI) above 45 kg/m2
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults subjects
- Cutaneous sarcoidosis with characteristic skin biopsy histology
- A CSAMI activity score ≥ 10
- Weight > 40 kg to < 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2
Who cannot take part
- History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix
- High risk of thrombosis or cardiovascular disease
- Active or recent infection
- High risk of herpes zoster
Where in United Kingdom
Also in 8 other countries, 54 sites
- CoventryHospital not named in the registryContact: Clinical Trial AdministratorTaking people
- LondonHospital not named in the registryContact: Clinical Trial AdministratorTaking people
- ManchesterHospital not named in the registryContact: Clinical Trial AdministratorTaking people
About the trial
What the trial wants to find out
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
The 5 groups in the trial
- Part 1: Brepocitinib Dose Level 1Treatment being tested
Oral Brepocitinib
Treatment: Oral Brepocitinib
- Part 1: Brepocitinib Dose Level 2Treatment being tested
Oral Brepocitinib
Treatment: Oral Brepocitinib
- Part 1: PlaceboPlacebo, for comparison
Treatment: Oral Placebo
- Part 2: Brepocitinib Dose Level 1Treatment being tested
Oral Brepocitinib
Treatment: Oral Brepocitinib
- Part 2: PlaceboPlacebo, for comparison
Treatment: Oral Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis
- Plain-language title
- Brepocitinib taken by mouth for adults with skin sarcoidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Record updated
- 3 November 2026